Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Antibodies

<
<<
Previous
Page 1 of 4
Next
>>
>
1 to 25 of 90 records
per page:

Small Molecule	Antibody	Perturbagen Target	Perturbagen Class	GR50 lower quartile	GR50 median	GR50 upper quartile	GRmax lower quartile	GRmax median	GRmax upper quartile	GRinf lower quartile	GRinf median	GRinf upper quartile	Hill Coefficient lower quartile	Hill Coefficient median	Hill Coefficient upper quartile	GR_AOC lower quartile	GR_AOC median	GR_AOC upper quartile	GEC50 lower quartile	GEC50 median	GEC50 upper quartile
Sigma A6730		AKT	AKT	2.0327	6.5660	11.2198	-0.9178	-0.8320	-0.6777	-1.0000	-1.0000	-0.9546	0.9310	1.3794	2.0044	0.2439	0.2875	0.4042	6.3004	13.6236	19.0461
Triciribine		AKT	AKT	0.1497	1.0069	10.2321	-0.2208	0.0730	0.3595	-0.6783	-0.3270	0.0049	0.3693	0.5173	0.9769	0.1961	0.3180	0.4712	0.2958	1.3169	18.2553
AG1478		EGFR	ErbB	8.7673	51.6075	100.0000	-0.0710	0.2684	0.6341	-0.3109	-0.0273	0.4206	0.8939	1.7205	2.6373	0.0902	0.1531	0.2936	3.7212	36.6666	94.4655
	Cetuximab	EGFR	ErbB	100.0000	100.0000	100.0000	0.7284	0.8755	0.9754	0.5964	0.8555	0.9754	0.0000	0.0000	0.7916	-0.0099	0.0234	0.0674	3.7461	100.0000	100.0000
Erlotinib		EGFR	ErbB	6.4716	35.2468	100.0000	0.0317	0.4006	0.6354	-0.8374	-0.1704	0.3788	0.3155	0.7139	1.8126	0.0351	0.1228	0.2396	13.2839	41.2968	100.0000
Gefitinib		EGFR	ErbB	6.6704	12.9191	28.3915	-0.2671	0.0424	0.3018	-0.8465	-0.5620	-0.2259	0.9170	1.3719	2.5436	0.0767	0.1382	0.2408	9.0805	26.2291	41.5832
Afatinib		EGFR/HER2	ErbB	0.1253	1.5517	2.4757	-0.9553	-0.9200	-0.8460	-1.0000	-1.0000	-0.9391	0.5080	1.0283	1.7263	0.4620	0.5435	0.6679	1.1116	3.3143	4.9447
Lapatinib		EGFR/HER2	ErbB	31.2806	100.0000	100.0000	0.4954	0.7950	0.9113	0.2428	0.7519	0.9066	0.0000	0.2457	1.3492	0.0247	0.0703	0.1302	1.5972	63.5403	100.0000
LBH589		HDAC	HDAC	0.0792	0.1432	0.2719	-0.9159	-0.8072	-0.7128	-0.9155	-0.7955	-0.6832	1.1720	1.5004	2.1649	0.5471	0.6739	0.7846	0.1472	0.2600	0.4626
Oxamflatin		HDAC	HDAC	0.6664	0.9513	1.6592	-0.9525	-0.8858	-0.8199	-1.0000	-0.9857	-0.8929	1.0334	1.2610	1.4776	0.4375	0.5175	0.6006	1.6681	2.6703	3.8183
Trichostatin A		HDAC	HDAC	6.5374	11.5225	17.5553	-0.9202	-0.8512	-0.7541	-0.9053	-0.8178	-0.6756	1.3647	1.8955	2.2777	0.6490	0.7724	0.9158	11.0302	20.2024	30.2620
Valproic acid		HDAC	HDAC	100.0000	100.0000	100.0000	-0.8969	-0.6820	-0.4277	-0.5381	-0.3207	-0.1180	1.1443	1.2884	1.4704	0.1935	0.2464	0.2891	100.0000	100.0000	100.0000
Vorinostat		HDAC	HDAC	72.1503	100.0000	100.0000	-0.8970	-0.8099	-0.5591	-0.9320	-0.8403	-0.5970	1.0273	1.3201	1.6251	0.4794	0.5820	0.7389	100.0000	100.0000	100.0000
17-AAG		HSP90	HSP90	0.0442	0.0876	0.1713	-0.7309	-0.6010	-0.3062	-0.5924	-0.4000	-0.2370	0.8987	1.8748	3.3051	0.4754	0.6987	0.8282	0.0680	0.1218	0.3890
Geldanamycin		HSP90	HSP90	0.0092	0.0240	0.0425	-0.4324	-0.2962	-0.0904	-0.3507	-0.2347	-0.0323	1.6732	2.3748	3.3908	0.6486	0.7709	0.9035	0.0116	0.0269	0.0560
JNK-IN-5A		JNK	JNK	1.8491	14.2132	100.0000	-0.1818	0.1302	0.4971	-0.4099	0.0435	0.4984	0.0000	3.1821	4.9999	0.0989	0.2367	0.3549	1.4898	12.5032	100.0000
L-779450		BRAF	MAPK	12.8318	28.9246	48.0158	-0.2622	0.2749	0.3891	-1.0000	-0.6190	-0.1023	1.0435	1.8204	3.7221	0.0544	0.0922	0.1394	20.7244	44.1580	61.2878
XRP44X		ELK3	MAPK	0.7816	1.1482	1.8976	-0.2021	0.0602	0.2789	-0.1369	0.0575	0.2934	1.8769	3.3942	4.9998	0.2905	0.3686	0.4637	0.6561	1.0109	1.3678
FR180204		ERK1/2	MAPK	56.2203	100.0000	100.0000	0.4862	0.6317	0.8238	-0.1433	0.2500	0.7055	0.0180	0.6403	1.9539	0.0470	0.0722	0.1058	65.9938	100.0000	100.0000
FTase Inhibitor I		Ftase	MAPK	100.0000	100.0000	100.0000	0.7715	0.8851	0.9752	0.7468	0.8851	0.9752	0.0000	0.0000	0.0000	0.0099	0.0556	0.0941	100.0000	100.0000	100.0000
PD 98059		MEK	MAPK	100.0000	100.0000	100.0000	0.5235	0.6650	0.8191	-0.1517	0.5395	0.8149	0.0000	0.2473	0.7779	0.0463	0.0842	0.1501	32.4005	100.0000	100.0000
PD184352		MEK	MAPK	31.0822	100.0000	100.0000	0.4258	0.7584	0.9084	-0.2272	0.7139	0.9084	0.0000	0.0524	0.4766	0.0368	0.0888	0.1432	63.7076	100.0000	100.0000
Selumetinib		MEK	MAPK	3.4703	100.0000	100.0000	0.2888	0.6993	0.8618	0.1384	0.6524	0.8687	0.0000	0.4990	0.9393	0.0510	0.1233	0.3040	0.3246	2.6951	100.0000
Trametinib		MEK	MAPK	0.1119	60.3200	100.0000	0.2676	0.5669	0.7582	0.2515	0.4183	0.5896	0.4854	1.1532	1.7735	0.0718	0.1864	0.3779	0.0100	0.4479	33.6419
Nutlin 3a		MDM2	MDM2	15.2348	24.3890	41.8634	-0.3252	-0.0482	0.2155	-1.0000	-0.8163	-0.2697	1.1456	1.7429	2.5635	0.0828	0.1397	0.2099	23.6810	39.7952	62.9892

<
<<
Previous
Page 1 of 4
Next
>>
>
1 to 25 of 90 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)